We are live on ! Find out more
CELG.RT

Bristol-Myers Squibb Rights

22 hedge funds and large institutions have $303K invested in Bristol-Myers Squibb Rights in 2021 Q3 according to their latest regulatory filings, with 2 funds opening new positions, 4 increasing their positions, 2 reducing their positions, and 1 closing their positions.

New
Increased
Maintained
Reduced
Closed

100% more first-time investments, than exits

New positions opened: 2 | Existing positions closed: 1

100% more repeat investments, than reductions

Existing positions increased: 4 | Existing positions reduced: 2

61% more capital invested

Capital invested by funds: $189K → $303K (+$114K)

5% more funds holding

Funds holding: 2122 (+1)

0% more ownership

Funds ownership: 0.03%0.03% (+0%)

Holders
22
Holders Change
+1
Holders Change %
+4.76%
% of All Funds
0.39%
Holding in Top 10
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
New
2
Increased
4
Reduced
2
Closed
1
Calls
Puts
Net Calls
Net Calls Change

CELG.RT Hedge Fund Activity: Q3 2021 in Review

22 of the 5,713 institutional investors tracked by Wall St. Rank reported a position in Bristol-Myers Squibb Rights (CELG.RT) for Q3 2021, worth a combined $303K — up 61% from $189K a quarter earlier.

Buyers outnumbered sellers: 2 funds opened new CELG.RT positions and 1 closed out — a net gain of 1 holder — while 4 added to existing stakes and 2 trimmed.

The largest buyer was Boothbay Fund Management, opening a new position worth an estimated $28.6K. The largest seller was Maven Securities, exiting entirely with an estimated $47K sold.

  • 22 institutional investors held Bristol-Myers Squibb Rights (CELG.RT) as of Q3 2021, up from 21 in Q2 2021.
  • Funds reported $303K of Bristol-Myers Squibb Rights stock for Q3 2021, up 61% quarter-over-quarter.
  • 2 funds opened new Bristol-Myers Squibb Rights positions in Q3 2021 and 1 closed out, a net change of +1 holder.
  • The largest Bristol-Myers Squibb Rights buyer in Q3 2021 was Boothbay Fund Management, an estimated $28.6K added.
  • The largest Bristol-Myers Squibb Rights seller in Q3 2021 was Maven Securities, an estimated $47K sold.

Based on aggregated 13F filings for Q3 2021.